Allied Corp. (ALID) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Allied Corp. (ALID) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 39/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Allied Corp. (ALID) Resumen de Asistencia Médica y Tuberías
Allied Corp. operates within the cannabis industry, focusing on hemp-derived CBD products and the development of treatments for mental health conditions like PTSD. The company's dual-segment structure allows for targeted operations in both Colombia and the United States, addressing the growing market for cannabis-related health and wellness solutions.
Tesis de Inversión
Allied Corp. presents a speculative investment thesis centered on its development of novel treatments for PTSD and its existing line of hemp-derived CBD products. The company's focus on ALID 10 and ALID 11 offers potential upside if clinical trials demonstrate efficacy and regulatory approvals are secured. However, the company's current market capitalization of $0.00B and negative free cash flow of $-0.00B indicate significant financial challenges. The company's success hinges on navigating the complex regulatory landscape of the cannabis industry and successfully commercializing its products. Investors should carefully consider the risks associated with investing in a small-cap company in a rapidly evolving industry.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap: $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Free Cash Flow: $-0.00B reflects the company's current need for external funding to sustain operations and growth initiatives.
- Beta: -0.82 suggests the stock is less volatile than the market, but this may also reflect limited trading activity.
- Operates in two segments: Allied Colombia and Allied Corp., allowing for focused operations in cultivation/production and product development/distribution, respectively.
- Developing ALID 10 and ALID 11 for PTSD treatment, representing a high-potential, high-risk venture into pharmaceutical applications of cannabis.
Competidores y Pares
Fortalezas
- Focus on developing treatments for PTSD.
- Operates in two distinct segments.
- Offers a range of hemp-based CBD products.
- Established presence in the US market.
Debilidades
- Limited financial resources.
- Negative free cash flow.
- Small market capitalization.
- Reliance on OTC market for trading.
Catalizadores
- Upcoming: Clinical trial results for ALID 10 and ALID 11 for PTSD treatment.
- Ongoing: Expansion of distribution network for CBD products.
- Ongoing: Regulatory developments in the cannabis industry.
- Upcoming: Potential partnerships with other companies in the cannabis space.
- Ongoing: Development of new CBD-based products.
Riesgos
- Potential: Regulatory changes in the cannabis industry could negatively impact the company's operations.
- Ongoing: Competition from larger cannabis companies with greater resources.
- Potential: Failure to obtain regulatory approval for ALID 10 and ALID 11.
- Ongoing: Limited financial resources and negative free cash flow.
- Potential: Fluctuations in the price of hemp and CBD.
Oportunidades de crecimiento
- Expansion of CBD Product Line: Allied Corp. has the opportunity to expand its line of hemp-based CBD natural health products, including beauty and skincare products, and foods and beverages. The global CBD market is projected to reach billions of dollars in the coming years, driven by increasing consumer demand for natural health and wellness products. By introducing new and innovative CBD products, Allied Corp. can capture a larger share of this growing market. Timeline: Ongoing.
- Development and Commercialization of ALID 10 and ALID 11: Allied Corp.'s development of ALID 10 and ALID 11 for the treatment of PTSD represents a significant growth opportunity. PTSD affects millions of people worldwide, and there is a significant unmet need for effective treatments. If Allied Corp. can successfully develop and commercialize these treatments, it could generate substantial revenue and establish itself as a leader in the field of cannabis-based pharmaceuticals. Timeline: 3-5 years.
- Strategic Partnerships: Allied Corp. can pursue strategic partnerships with other companies in the cannabis industry, such as cultivators, manufacturers, and distributors. These partnerships can help Allied Corp. to expand its reach, access new markets, and improve its operational efficiency. For example, a partnership with a large distributor could help Allied Corp. to get its products into more retail stores. Timeline: Ongoing.
- International Expansion: Allied Corp. can expand its operations into new international markets. The cannabis industry is growing rapidly in many countries around the world, and Allied Corp. can capitalize on this growth by establishing a presence in these markets. However, it is important to carefully consider the regulatory environment in each country before entering a new market. Timeline: 2-3 years.
- Research and Development: Allied Corp. can continue to invest in research and development to develop new and innovative cannabis-based products and treatments. This will help Allied Corp. to stay ahead of the competition and maintain its position as a leader in the cannabis industry. For example, Allied Corp. could invest in research to develop new strains of cannabis with specific therapeutic properties. Timeline: Ongoing.
Oportunidades
- Expansion of CBD product line.
- Commercialization of ALID 10 and ALID 11.
- Strategic partnerships.
- International expansion.
Amenazas
- Regulatory changes in the cannabis industry.
- Competition from larger cannabis companies.
- Challenges in obtaining regulatory approval for ALID 10 and ALID 11.
- Fluctuations in the price of hemp and CBD.
Ventajas competitivas
- Proprietary formulations for CBD products.
- Intellectual property related to ALID 10 and ALID 11.
- Established presence in the US market for hemp-derived products.
Acerca de ALID
Allied Corp., headquartered in Kelowna, Canada, is a cannabis company engaged in the development, manufacture, and marketing of hemp-derived cannabis products primarily in the United States. The company operates through two distinct segments: Allied Colombia and Allied Corp. These segments allow the company to focus on different aspects of the cannabis market, from cultivation and production to product development and distribution. Allied Corp. offers a range of hemp-based CBD natural health products, including beauty and skincare products, as well as foods and beverages. A key aspect of Allied Corp.'s business is its research and development efforts, particularly in the area of mental health. The company is developing ALID 10 and ALID 11, novel treatments for post-traumatic stress disorder (PTSD) and related mental health conditions. These treatments target the 5-HT2 receptor and related physiological pathways, representing a potentially innovative approach to addressing these conditions. Allied Corp. aims to establish itself as a leader in the cannabis industry by providing high-quality products and developing innovative treatments for unmet medical needs.
Qué hacen
- Develops hemp-derived cannabis products.
- Manufactures hemp-derived cannabis products.
- Markets hemp-derived cannabis products in the United States.
- Operates in two segments: Allied Colombia and Allied Corp.
- Offers hemp-based CBD natural health products.
- Develops beauty and skincare products.
- Develops foods and beverages.
- Develops ALID 10 and ALID 11 for PTSD treatment.
Modelo de Negocio
- Develops and manufactures hemp-derived cannabis products.
- Markets and sells these products directly to consumers and through retail channels.
- Generates revenue through the sale of CBD products, beauty and skincare items, and potentially pharmaceuticals.
Contexto de la Industria
Allied Corp. operates in the rapidly evolving cannabis industry, which is experiencing significant growth and regulatory changes. The market for CBD products is expanding, driven by increasing consumer awareness of the potential health benefits of cannabis. However, the industry is also highly competitive, with numerous companies vying for market share. Allied Corp.'s focus on developing treatments for PTSD differentiates it from many of its competitors, but also exposes it to the risks associated with pharmaceutical development and regulatory approval. The company's success will depend on its ability to navigate the complex regulatory landscape and effectively market its products.
Clientes Clave
- Consumers seeking natural health and wellness products.
- Individuals looking for alternative treatments for mental health conditions.
- Retailers who sell CBD products and related items.
Finanzas
Gráfico e información
Precio de la acción de Allied Corp. (ALID): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para ALID.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ALID.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ALID.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ALID en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Información del mercado OTC de ALID
The OTC Other tier represents the lowest tier of the OTC market, indicating that Allied Corp. may not meet the minimum financial standards or reporting requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and prospects. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Going concern risk.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Confirm share structure and outstanding shares.
- Company has a functional website.
- Company has a physical address and contact information.
- Company has a detailed business plan.
- Company is actively developing and marketing products.
- Company has a management team with relevant experience.
ALID Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar ALID?
Allied Corp. (ALID) actualmente tiene una puntuación IA de 39/100, indicando puntuación baja. Fortaleza clave: Focus on developing treatments for PTSD.. Riesgo principal a monitorear: Potential: Regulatory changes in the cannabis industry could negatively impact the company's operations.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ALID?
ALID actualmente puntúa 39/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ALID?
Los precios de ALID se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ALID?
La cobertura de analistas para ALID incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ALID?
Las categorías de riesgo para ALID incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory changes in the cannabis industry could negatively impact the company's operations.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ALID?
La relación P/E para ALID compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ALID sobrevalorada o infravalorada?
Determinar si Allied Corp. (ALID) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ALID?
Allied Corp. (ALID) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is based on limited information available for OTC-listed companies.
- Analyst consensus is not available due to lack of coverage.
- OTC analysis is based on general characteristics of the OTC Other tier.